


Top Gainer and Loser				
Company	CLOSE	YCP	% Change	VOLUME
Top Gainer				
KPPL	20	19	9.73	6,978,308
PDL	13	12	9.48	9,281,746
ETL	11	10	9.28	7,146,204
CONTININS	44	41	7.65	1,883,722
AMBEEPHA	844	786	7.38	16,295

Top Loser				
Company	CLOSE	YCP	% Change	VOLUME
Top Loser				
ARAMIT	266	282	(5.82)	67,972
EMERALDOIL	114	121	(5.46)	1,288,784
USMANIAGL	53	56	(4.32)	13,883
JUTESPINN	328	343	(4.26)	3,304
CAPITEGBF	12	13	(3.88)	3,221,701

YCP = Yesterday Closing Price

DSE in Last 1 Month



Top Stocks (Turnover based)

INSTRUMENT	Price	Value (Mn BDT)	Volume
FUWANGFOOD	32	171	5,246,403
EMERALDOIL	114	151	1,288,784
MONNOCERA	103	146	1,446,394
KPPL	20	141	6,978,308
BDTHAI	20	125	6,340,719
CENTRALPHL	15	124	8,123,378
PDL	13	117	9,281,746
KBPPWBIL	69	83	1,229,946
SKTRIMS	30	81	2,676,028
CONTININS	44	79	1,883,722

Market Statistics

Today	% Change
Market Cap (In Mn BDT)	7,752,425
Total Volume (In Mn BDT)	3,608
DSEX	6,257
DSES	1,359
DS-30	2,119
Market P/E	20.6

World Markets


Indices	% Change	Currency	Rates
NASDAQ	14,104	USD	110.97
HANG SENG	17,833	GBP	137.63
BSE-SENSEX	66,283	EUR	120.47

Exchange Rates

Market Commentary

Today's Market / DSEX (Prime bourse : DSE / Dhaka Stock Exchange Ltd.) ended down 0.02% with 44.07% decline in total turnover. FUWANGFOOD, EMERALDOIL, MONNOCERA, KPPL, BDTHAI stocks dominated today's market turnover. However, KPPL was today's best performer having the highest growth of 9.73% from YCP. DSEX reflected a bearish mode through the day resulting in 62 issues declined out of 293 total issues traded.


DSE Sectoral Comparison today in turnover (In Mn BDT)



DSE Sectoral Comparison in P/E

Sector name	P/E Ratio
Bank	6
Cement	16
Ceramics	141
Engineering	47
Financial	50
Food & Allied	40
Fuel & Power	22
Insurance	20
IT Sector	25
Jute	155
Miscellaneous	27
Mutual Funds	29
Paper & Printing	36
Pharmaceuticals &	32
Services & Real Es	24
Tannery industries	39
Telecommunication	14
Textile	32
Average	20.6

DSE Sectoral Comparison in Market Cap



DSE's Important News Today

DOMINAGE

Dividend Declaration

The Board of Directors has recommended 0.50% Cash dividend for general shareholders other than Sponsors/Directors for the year ended June 30, 2023. The Sponsors/Directors hold 30,980,609 shares of the Company and the cash payable to the general shareholders is Tk. 3,580,970.00. Date of AGM: 30.12.2023, Time: 3:00 PM, Venue: Digital Platform. Record Date: 06.12.2023. The Company has also reported EPS of Tk. 0.04, NAV per share of Tk. 17.14 and NOCFPS of Tk. 1.40 for the year ended June 30, 2023 as against Tk. 0.55, Tk. 17.23 and Tk. 2.61 respectively for the year ended June 30, 2022.

ARAMIT

Dividend Declaration

The Board of Directors recommended 25% Cash dividend for the year ended June 30, 2023. Date of AGM: 30.12.2023, Time: 10:30 AM, Venue: Digital Platform. Record date: 06.12.2023. The Company has also reported EPS of Tk. 4.01, NAV per share of Tk. 144.99 and NOCFPS of Tk. 5.69 for the year ended June 30, 2023 as against Tk. 8.25, Tk. 152.28 and Tk. 5.11 respectively for the year ended June 30, 2022.

SSSTEEL

Dividend Declaration

The Board of Directors has recommended 2% Cash dividend to general shareholders other than sponsors and directors for the year ended June 30, 2023. Date of AGM: 31.12.2023, Time: 2:00 PM, Venue: Digital Platform. Record Date: 05.12.2023. The Company has reported consolidated EPS of Tk. 0.05, consolidated NAV per share (with revaluation) of Tk. 23.99, consolidated NAV per share (without revaluation) of Tk. 21.50 and consolidated NOCFPS of Tk. (2.46) for the year ended June 30, 2023 as against Tk. 1.87, Tk. 24.05, Tk. 21.41 and Tk. (4.04) respectively for the year ended June 30, 2022.

GHCL

Dividend Declaration

The Board of Directors has recommended No Dividend for the year ended June 30, 2023. Date of AGM: 21.12.2023, Time: 10:30 AM, Venue: Digital Platform. Record Date: 06.12.2023. The Company has also reported EPS of Tk. (5.77), NAV per share of Tk. 47.85 and NOCFPS of Tk. (2.45) for the year ended June 30, 2023 as against Tk. (1.57), Tk. 53.68 and Tk. (0.50) respectively for the year ended June 30, 2022.

BEACONPHAR

Credit Rating Result

Credit Rating Agency of Bangladesh Limited (CRAB) has assigned the Surveillance entity rating of the Company as "AA3" in the long term and "ST-2" in the short term along with Stable outlook based on audited financial statements up to June 30, 2023, Bank liability position as on September 30, 2023 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

Other News Today

Square Pharma gains record profit in Q1 on high demand for dengue drugs - Source: The Financial Express

Square Pharmaceuticals witnessed the highest-ever quarterly profit in July-September this year, driven by a double-digit growth in sales revenue. The sales got a boost in the quarter, compared to the previous quarter, mainly because of an escalation in the demand for dengue-related drugs. The leading drug manufacturer in Bangladesh secured a consolidated profit of more than Tk 6 billion in July-September of FY24, a 9.10 per cent increase from the same quarter a year before. Accordingly, the earnings per share stood at Tk 6.77, up from Tk 6.20 for the same quarter of the previous year, according to its unaudited financial statement published on Tuesday. Square Pharma, the flagship company of Square Group, registered a 15 per cent year-on-year sales growth to Tk 18.46 billion in the quarter through September. Dengue-related medicine sales highly contributed to the overall sales growth, said Md Zahangir Alam, chief financial officer of Square Pharmaceuticals. "As we are the market leader in the pharmaceuticals sector, people trusted Square Pharma's medicines, which helped the top line to grow, leading to bottom-line growth as well," he said. Bangladesh has been experiencing its most severe dengue outbreak this year, particularly in the July-September quarter. Some 1,520 dengue patients have died, while around 300,000 other have been infected with dengue until Wednesday this year. More than 6,000 dengue patients are still admitted to different hospitals across the country, according to the Directorate General of Health Services (DGHS). Mr Alam said the business continued to grow every year in both sales and profit on local consumers' and health practitioners' faith in its products. In ensuring quality products, Square Pharma has been putting more emphasis on research and development, he said. Square Pharma gained a record annual profit of around Tk 19 billion in FY23. The board declared the highest-ever cash dividend of 105 per cent for FY23. The drug manufacturer, which expanded its market share to more than 20 per cent in FY23 from over 18 per cent a year ago, seeks to further bolster its position in the domestic market. Though Square Pharma's business focus is on the local market, it has gained a foothold in the export market too, having supplied products to well-regulated markets, such as the US and the EU nations. Recently, Square Pharma signed contract manufacturing deals with non-listed Aristopharma and Euro Pharma to produce some products for Square Pharma to meet the growing demand for its existing products and to introduce new products. Square Pharmaceuticals' stock, considered one of the best performing blue-chip stocks, took off from the floor in July this year after eight months following the business deal with Aristopharma. The stock rose 0.52 per cent to close at Tk 211.90 on Wednesday.

MTB Securities Ltd.

WW Tower (Level 4), 68 Motiheel C/A, Dhaka - 1000, Bangladesh
Telephone : +88 02 9347567 | Fax : +88 02 9348657
Email: info.query@mtbsecurities.com
Website: www.mtbsecurities.com

Disclaimer: Estimates and projections are our own and are based on assumptions we believe to be reasonable. Information presented herein, while obtained from sources we believe to be reliable, is not guaranteed as to accuracy or completeness. Neither the information nor any opinion expressed herein constitutes a solicitation of the purchase or sale of any security. This report is intended for distribution to our valuable clients to present the daily Market Summary only.